Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
15.93 USD | +1.46% | +0.96% | -17.38% |
Financials (USD)
Sales 2024 * | 187M | Sales 2025 * | 164M | Capitalization | 1.43B |
---|---|---|---|---|---|
Net income 2024 * | -325M | Net income 2025 * | -382M | EV / Sales 2024 * | 4.36 x |
Net cash position 2024 * | 610M | Net cash position 2025 * | 270M | EV / Sales 2025 * | 7.06 x |
P/E ratio 2024 * |
-4.08
x | P/E ratio 2025 * |
-3.67
x | Employees | 577 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 58.87% |
Latest transcript on Arcus Biosciences, Inc.
1 day | +1.29% | ||
1 week | +0.96% | ||
Current month | +3.09% | ||
1 month | -9.46% | ||
3 months | +3.15% | ||
6 months | -4.09% | ||
Current year | -17.80% |
Managers | Title | Age | Since |
---|---|---|---|
Juan Jaen
FOU | Founder | 66 | 14-12-31 |
Terry Rosen
CEO | Chief Executive Officer | 65 | 14-12-31 |
Robert Goeltz
DFI | Director of Finance/CFO | 51 | 20-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Terry Rosen
CEO | Chief Executive Officer | 65 | 14-12-31 |
Kathryn Falberg
BRD | Director/Board Member | 63 | 17-09-17 |
Yasunori Kaneko
BRD | Director/Board Member | 69 | 15-04-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.88% | 11 M€ | -6.03% | - | |
0.28% | 27 M€ | -4.14% | - | |
0.12% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-06 | 16.1 | +2.55% | 66 862 |
24-05-03 | 15.7 | +1.29% | 538,283 |
24-05-02 | 15.5 | 0.00% | 455,120 |
24-05-01 | 15.5 | +1.77% | 613,059 |
24-04-30 | 15.23 | -2.56% | 553,394 |
Delayed Quote Nyse, May 03, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.80% | 1.43B | |
+25.69% | 47.9B | |
+47.47% | 41.42B | |
-3.46% | 40.7B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+0.17% | 12.15B | |
+28.07% | 12.14B | |
-1.24% | 11.99B |
- Stock Market
- Equities
- RCUS Stock